Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 plus atezolizumab versus standard of care in first-line extensive-stage small cell lung cancer
jRCT2031250359Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of turmetabart adizutecan, atezolizumab, etoposide, carboplatin and lurbinectedin in small cell lung cancer (SCLC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events and Progression-Free Survival (PFS). Started Dec 2025; status: recruiting.
02
Drugs
turmetabart adizutecanatezolizumabetoposidecarboplatinlurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031250359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250359.